MiNA Therapeutics Ltd has appointed Susan Clement-Davies and Robert Lechler as independent directors to help guide development of its pipeline of small activating RNA therapeutics. Ms Clement-Davies has more than 25 years of capital markets and investment banking experience, including as head of equity capital markets at Citigroup Global Markets Ltd. Professor Lechler has worked in academic medicine for more than 40 years including as head of Imperial College London’s Division of Medicine.
MiNA Therapeutics announced the appointments on 21 December 2021.
Copyright 2022 Evernow Publishing Ltd